Please assess the completion status of the following clinical trial:

Trial Title: Dose Confirmation Efficacy Study (V260-007)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy infants~Exclusion Criteria:~* History of abdominal disorders from a birth defect, intussusception, or abdominal surgery~* Known or suspected problems with immune system~* Fever at time of immunization~* Prior administration of a rotavirus vaccine~* History of known prior rotavirus disease~* Chronic diarrhea, or failure to thrive

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 12 Weeks
- Healthy Volunteers: t

Study Arms:
- RotaTeq™ at Expiry Potency (≈1.1 x 10^7 IU/Dose) (Type: EXPERIMENTAL): Three doses of RotaTeq™ (Rotavirus vaccine, live, oral, pentavalent)~administered 28 to 70 days apart.
- Placebo matching RotaTeq™ (Type: PLACEBO_COMPARATOR): Placebo matching RotaTeq™ administered 28 to 70 days apart.

Based on this trial design, predict the completion outcome and termination type (if applicable).